Table 3.
Summary of effects of various inhibitors and antagonists on 30 μm PE-induced contraction in rat small resistance artery, midsized muscular artery and large conduit aorta
| Small resistance artery | Midsized muscular artery | Large conduit artery | ||||
|---|---|---|---|---|---|---|
| Inhibitors or antagonists | Initial rising phase | Late sustained phase | Initial rising phase | Late sustained phase | Initial rising phase | Late sustained phase |
| PKC inhibitors (GF109203X, calphostin C) | +++ | +++ | ++ | ++ | ± | + or ++ |
| Ca2+-dependent PKC inhibitors (Gö-6976, PKC downregulation) | +++ | + or ++ | + | + | ND | ND |
| ROCK inhibitors (Y27632, H1152, GSK429286) | ± | + | ± | ++ | ± | +++ |
| PKC & ROCK inhibitors (GF109203X + Y27632) | +++ | +++ | ++ | +++ | + | +++ |
| Inhibition of Ca2+ release (ryanodine treatment) | +++ | ± or + | +++ | + | +++ | ++ |
| Inhibition of Ca2+ influx (nicardipine) | + or ++ | +++ | ± | ++ | ± | ++ |
| Inhibition of both release & influx (ryanodine + nicardipine) | +++ | +++ | +++ | ++ or +++ | +++ | ++ |
| α1A-antagonist (RS-100329) | +++ | +++ | ++ | + or ++ | ± or + | + |
| α1D-antagonist (BMY-7378) | ± | ± | ± or + | ± or + | +++ | +++ |
+++ represents a strong inhibition; ++, medial; +, small; ±, no change; ND, not determined.